How GLP-1 Drugs Work: The Science Behind Ozempic

A Hormone You Never Knew You Had

Every time you eat, your gut releases a small but powerful hormone called glucagon-like peptide-1, or GLP-1. It tells your pancreas to release insulin, signals your brain that you're full, and slows the emptying of your stomach. Under normal conditions, this hormone lasts just a few minutes in the bloodstream before enzymes break it down.

GLP-1 receptor agonists — the drug class behind household names like Ozempic, Wegovy, Mounjaro, and Zepbound — are engineered versions of this hormone designed to last much longer. When injected once a week (or, more recently, swallowed as a pill), they keep those satiety signals switched on for days, fundamentally changing how the body experiences hunger.

The Gut-Brain Connection

The drugs work through two main pathways. First, they act on the vagus nerve, the long highway of nerve fibers running from the gut to the brainstem. By activating GLP-1 receptors along this route, the drugs trigger satiety signals similar to those produced by a full stomach — even before significant food is consumed.

Second, and perhaps more surprisingly, these drugs cross into the brain itself. GLP-1 receptors sit in regions of the brain governing appetite, including the hypothalamus and the reward circuitry in the ventral tegmental area. When activated, they dampen the dopamine release associated with food cravings, effectively reducing food's psychological reward. This is likely why patients on these drugs report not just eating less, but wanting less food in the first place.

On top of these effects, GLP-1 agonists slow gastric emptying — meaning food lingers longer in the stomach, prolonging the sense of fullness after a meal.

From Gila Monster Venom to Blockbuster Drug

The story of GLP-1 drugs begins in an unlikely place: the saliva of the Gila monster lizard. In the early 1990s, researchers isolated a peptide called exendin-4 from the lizard's venom that mimicked human GLP-1 but resisted enzymatic breakdown. This led to exenatide, the first GLP-1 drug, approved by the FDA in 2005 for type 2 diabetes.

Danish pharmaceutical giant Novo Nordisk then developed semaglutide, a more potent and longer-lasting analog. Sold as Ozempic for diabetes and Wegovy for obesity, semaglutide demonstrated average weight loss of around 15–17% of body weight in clinical trials — results that had never been seen with any pill or non-surgical intervention before.

Eli Lilly answered with tirzepatide (Mounjaro, Zepbound), a dual agonist that activates both GLP-1 and a second hormone receptor, GIP. In head-to-head trials published in the New England Journal of Medicine, tirzepatide outperformed semaglutide on both blood sugar reduction and weight loss, with some patients losing up to 22% of their body weight.

Beyond the Scale: New Frontiers

Weight loss is no longer the only reason physicians prescribe these drugs. A landmark trial called SELECT — enrolling more than 17,500 patients — found that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) by 20%, even in patients who did not have diabetes, according to research reviewed by the Minneapolis Heart Institute Foundation. The FDA has since expanded approved uses to include certain forms of heart failure and peripheral artery disease.

Researchers are now exploring an even more unexpected frontier: addiction treatment. Because GLP-1 receptors are present in the brain's reward system, the drugs appear to blunt cravings for alcohol, opioids, and other substances. A large observational study reported by CNN found that GLP-1 users were significantly less likely to develop substance-use disorders or suffer serious addiction-related outcomes over a three-year period.

Other ongoing research, highlighted by the Harvard Gazette, is examining GLP-1's potential in treating Alzheimer's disease, metabolic liver disease, and inflammatory bowel conditions.

Side Effects and Limitations

The drugs are not without drawbacks. Nausea, vomiting, diarrhea, and constipation are the most common side effects, particularly at the start of treatment. More seriously, rare cases of pancreatitis and a potential link to a rare thyroid tumor (seen in animal studies) require ongoing monitoring.

Perhaps the most significant limitation is rebound weight gain. Studies show that most patients regain much of the lost weight within a year of stopping the medication, suggesting that for many people these drugs require indefinite use to maintain results — raising long-term cost and access questions, as weekly injections can cost over $1,000 per month without insurance coverage.

Why It Matters

Obesity affects roughly one billion people worldwide and is a driver of diabetes, cardiovascular disease, and certain cancers. For decades, medicine had no highly effective non-surgical treatment. GLP-1 drugs represent a genuine paradigm shift — not a shortcut, but a pharmacological tool that works with the body's own hormonal architecture. How broadly, and how equitably, that tool can be deployed remains one of medicine's most pressing open questions.